참고문헌
- Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med 1967; 276: 1163-7. https://doi.org/10.1056/NEJM196705252762101
- Scriver CR. The metabolic & molecular bases of inherited disease. 8th ed. New York, McGraw-Hill. 2001, pp 3733-74.
- Eng CM, Fletcher J, Wilcox WR, Waldek S, Scott CR, Sillence DO, et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 2007; 30: 184-92. https://doi.org/10.1007/s10545-007-0521-2
- Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999; 281: 249-54. https://doi.org/10.1001/jama.281.3.249
- Ramaswami U, Whybra C, Parini R, Pintos-Morell G, Mehta A, Sunder-Plassmann G, et al. Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr 2006; 95: 86-92.
- Ries M, Ramaswami U, Parini R, Lindblad B, Whybra C, Willers I, et al. The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents. Eur J Pediatr 2003; 162: 767-72. https://doi.org/10.1007/s00431-003-1299-3
- Manger B, Mengel E, Schaefer RM. Rheumatologic aspects of lysosomal storage diseases. Clin Rheumatol 2007; 26: 335-41. https://doi.org/10.1007/s10067-006-0299-x
- Mehta A, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A, Kampmann C, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004; 34: 236-42. https://doi.org/10.1111/j.1365-2362.2004.01309.x
- Wozniak MA, Kittner SJ, Tuhrim S, Cole JW, Stern B, Dobbins M, et al. Frequency of unrecognized Fabry disease among young European-American and African-American men with first ischemic stroke. Stroke 2010; 41: 78-81. https://doi.org/10.1161/STROKEAHA.109.558320
- Kotanko P, Kramar R, Devrnja D, Paschke E, Voigtlä5nder T, Auinger M, et al. Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J Am Soc Nephrol 2004; 15: 1323-9. https://doi.org/10.1097/01.ASN.0000124671.61963.1E
- Marchesoni CL, Roa N, Pardal AM, Neumann P, Cáeceres G, Martírnez P, et al. Misdiagnosis in Fabry disease. J Pediatr 2010; 156: 828-31. https://doi.org/10.1016/j.jpeds.2010.02.012
- Paira SO, Roverano S, Iribas JL, BarcelóHA. Joint manifestations of Fabry's disease. Clin Rheumatol 1992; 11: 562-5. https://doi.org/10.1007/BF02283120
- Madden S, Kelly L. Update on acute rheumatic fever: it still exists in remote communities. Can Fam Physician 2009; 55: 475-8.
- Hoffmann B, Beck M, Sunder-Plassmann G, Borsini W, Ricci R, Mehta A; FOS European Investigators. Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy-a retrospective analysis from the Fabry Outcome Survey. Clin J Pain 2007; 23: 535-42. https://doi.org/10.1097/AJP.0b013e318074c986
- Hoffmann B, Garcia de Lorenzo A, Mehta A, Beck M, Widmer U, Ricci R; FOS European Investigators. Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey). J Med Genet 2005; 42: 247-52. https://doi.org/10.1136/jmg.2004.025791
- Hoffmann B, Schwarz M, Mehta A, Keshav S; Fabry Outcome Survey European Investigators. Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Clin Gastroenterol Hepatol 2007; 5: 1447-53. https://doi.org/10.1016/j.cgh.2007.08.012
- Feriozzi S, Schwarting A, Sunder-Plassmann G, West M, Cybulla M; International Fabry Outcome Survey Investigators. Agalsidase alfa slows the decline in renal function in patients with Fabry disease. Am J Nephrol 2009; 29: 353-61. https://doi.org/10.1159/000168482
- Hughes DA, Elliott PM, Shah J, Zuckerman J, Coghlan G, Brookes J, et al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 2008; 94: 153-8. https://doi.org/10.1136/hrt.2006.104026
- Wraith JE, Tylki-Szymanska A, Guffon N, Lien YH, Tsimaratos M, Vellodi A, et al. Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease. J Pediatr 2008; 152: 563-70. https://doi.org/10.1016/j.jpeds.2007.09.007
- Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 2007; 146: 77-86. https://doi.org/10.7326/0003-4819-146-2-200701160-00148
피인용 문헌
- Pain management strategies for neuropathic pain in Fabry disease - a systematic review vol.16, pp.1, 2016, https://doi.org/10.1186/s12883-016-0549-8
- Fabry disease in children: a federal screening programme in Russia vol.176, pp.10, 2017, https://doi.org/10.1007/s00431-017-2992-y
- Fabry disease: Inherited deficiency of a lysosomal enzyme due to a Xq22 mutation with possible enzyme replacement therapy vol.78, pp.4, 2010, https://doi.org/10.1016/j.monrhu.2011.06.006